Expert Interview
Discussing United Therapeutics' Phase 3 results for Ralinepag, a once-daily oral prostacyclin for patients with Pulmonary Arterial Hypertension (PAH)
Ticker(s): UTHRInstitution: National Jewish Health
- Fellowship-trained pulmonologist and researcher who treats lung diseases such as pulmonary hypertension and lymphangioleiomyomatosisa
- Focus on the study of sexual dimorphisms in lung vascular remodeling and right ventricular (RV) adaptation in pulmonary hypertension (PH)
- Manages 325 patients with PAH
- Extremely familiar with Ralinepag
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
